| Press release | Press Release |
| 2026-07-08 | Press release | Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Develop |
| 2026-06-04 | Press release | Ovid Therapeutics to Participate in Upcoming Investor Conferences |
| 2026-06-03 | Press release | Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Direct |
| Press release | Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results |
| 2026-05-12 | Presentation | Download PDF file, (opens in new window) |
| 2026-04-08 | Press release | Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14 |
| Press release | Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Qu |
| 2026-03-18 | Presentation | Download PDF (opens in new window) |
| 2026-03-18 | Press release | Ovid Therapeutics Announces Pricing of $60 Million Private Placement |
| 2026-02-25 | Press release | Ovid Therapeutics to Participate in Upcoming Investor Conferences |
| 2026-01-12 | Presentation | Download PDF (opens in new window) |
| 2025-12-18 | Press release | Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC |
| Quarterly report | View full release of Q3 2025 Report, (opens in new window) |
| 2025-11-12 | Quarterly report | Quarterly Filing of Q3 2025 Report, (opens in new window) |
| Quarterly report | View full release of Q2 2025 Report, (opens in new window) |
| 2025-06-12 | Presentation | Biomarkers in Epilepsy Investor Event |
| Press release | Q1 |
| 2024-12-09 | Presentation | OV329 A potent GABA-AT inhibitor Does Not Accumulate in Mouse Retina A Pharmacokinetic Study to Differentiate Eye Accumulation between Vigabatrin |
| 2024-12-06 | Presentation | Evaluation of Anticonvulsant Efficacy of the KCC2 Activator, OV350, in a Rat Model of Nerve Agent Poisoning |
| 2024-11-13 | Presentation | KCC2 Download Day |
| 2024-11-12 | Press release | Q3 |
| 2024-09-25 | Presentation | Evaluation of the Potential Accumulation of OV329 in the Brain, Retina and Eye Following Continuous Infusion |
| 2024-08-13 | Press release | Q2 |
| 2024-06-30 | Press release | Q4 |
| 2024-05-14 | Press release | Q1 |
| 2024-03-08 | Press release | Q4 |
| 2023-11-03 | Press release | Q3 |
| 2023-10-15 | Presentation | Potentiation of KCC2 shows Neuroprotective and Anti-inflammatory Effects in Kainic Acid-Induced Refractory Status Epilepticus |
| 2023-08-04 | Press release | Q2 |
| 2023-05-05 | Press release | Q1 |
| 2023-03-13 | Press release | Q4 |
| 2022-11-08 | Press release | Q3 |
| 2022-08-09 | Press release | Q2 |
| 2022-06-06 | Presentation | 2022 Epilepsy Foundation Pipeline Conference |
| 2022-06-03 | Presentation | EILAT XVI Conference on New Antiepileptic Drugs and Devices |
| Press release | Press Release |
| 2022-05-10 | Press release | Q1 |
| 2022-03-15 | Press release | Q4 |
| 2021-08-16 | Press release | Q2 |